Physician profile
Barclay A Monaster
NPI 1962418640
$9,992.72
in general payments reported to CMS, 2019-2025
52 companies · $2,576 in 2025
The $2,576 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2021: $792 · 2022: $1,870 · 2023: $1,933 · 2024: $2,691 · 2025: $2,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,119 · Education: $80.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,118.58 |
| Education | $80.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,002.85 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $1,033.57 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $943.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $694.20 | 2021-2025 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $644.21 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $595.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $592.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $313.91 | 2022-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Lilly USA, LLC | $289.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $276.30 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $240.37 | 2022-2025 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $231.73 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.42 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $163.56 | 2019-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $158.62 | 2021-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barclay Monaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.